It is truncated analogue of growth hormone releasing hormone (GHRH), which was developed in 1980s from original GRF 1-29, but with purposefully prolonged half-life to ensure better therapeutical use
*Based on average results reported by KLOwen
Members gain access to detailed protocols, interactive calculators like the reconstitution calculator and cost calculator , and a community of experienced researchers who can share practical insights
Description GHK-Cu is a synthetic copper-binding tripeptide (Copper Tripeptide-1) supplied as a lyophilized research material for in vitro and analytical laboratory applications
Other GLP-1R agonists have demonstrated extensive pleiotropic effects, including benefits in managing comorbidities such as osteoarthritis, cardiovascular disease, and neurodegenerative disorders
Wajner M, Latini A, Wyse AT, Dutra-Filho CS